Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC)

17 Feb 2026 08:49 CET

OSLO, Norway, February 17, 2026 — Lytix Biopharma AS (“Lytix”) (Euronext Growth
Oslo: LYTIX), a clinical-stage immuno-oncology company, today announced the
publication of a review article in the Journal of ImmunoTherapy of Cancer
(JITC).

The article, “Immunobiological mechanisms of action of oncolytic peptides,” was
created in collaboration with the company’s scientific collaborators at the
Institut Gustave Roussy (France) and Fox Chase Cancer Center (USA).

Bridging the Gap in Cancer Treatment
While traditional therapies often struggle with "cold" tumors, or cancers that
the immune system fails to recognize, oncolytic peptides provide a dual-action
solution. The article summarizes how these peptides do more than just destroy
cancer cells; they fundamentally reprogram the tumor microenvironment.

Additionally, the publication highlights ruxotemitide (also known as
LTX-315/VP-315), Lytix’s leading candidate, noting that recent clinical data
show that LTX-315 can produce complete and lasting responses in patients with
Basal Cell Carcinoma (BCC) and exhibits significant activity in "immunologically
cold" tumors that other therapies often overlook.

“This review not only confirms our core scientific approach but also acts as a
key resource for the oncology community as we progress toward more oncolytic
peptide/molecule-based treatments," said Øystein Rekdal, PhD, Founder and CEO of
Lytix Biopharma.

About JITC and SITC
The Journal of ImmunoTherapy of Cancer (JITC) is the official, peer-reviewed
journal of the Society for Immunotherapy of Cancer (SITC). As a leading
open-access platform for high-impact research, JITC is committed to advancing
the science and clinical practice of cancer immunology.

Access the Full Article: https://jitc.bmj.com/content/14/2/e013337

For more information:
Keith Bowermaster, APR, CCMP
Mighty Spark Communications
kbowermaster@mightysparkcommunications.com

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma’s lead
product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule
representing a new approach to maintaining durable anti-cancer immunity. Lytix
Biopharma has a pipeline of molecules that work across multiple cancer
indications and treatment settings, both as mono- and combination therapy. Lytix
is listed on Euronext Growth Oslo under the ticker LYTIX.

For more information, visit www.lytixbiopharma.com

More information:
Access the news on Oslo Bors NewsWeb site